Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission
Status:
Completed
Trial end date:
2019-12-06
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of etanercept monotherapy compared to
methotrexate monotherapy on maintenance of remission in participants with rheumatoid
arthritis (RA) who were on etanercept plus methotrexate therapy.
This is a multicenter, randomized withdrawal, double-blind controlled study in participants
with rheumatoid arthritis on etanercept plus methotrexate therapy who are in very good
disease control for 6 months prior to study entry. The study will consist of a 30-day
screening period, a 24-week open label run-in period, a 48-week double-blind treatment period
and a 30-day safety follow-up period.